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ABSTRACT
Tumors develop numerous strategies to fine-tune inflammation and avoid 
detection and eradication by the immune system. The identification of mechanisms 
leading to local immune dysregulation is critical to improve cancer therapy. We here 
demonstrate that Interleukin-1 receptor 8 (IL-1R8 - previously known as SIGIRR/
TIR8), a negative regulator of Toll-Like and Interleukin-1 Receptor family signaling, 
is up-regulated during breast epithelial cell transformation and in primary breast 
tumors. IL-1R8 expression in transformed breast epithelial cells reduced IL-1-
dependent NF-κB activation and production of pro-inflammatory cytokines, inhibited 
NK cell activation and favored M2-like macrophage polarization. In a murine breast 
cancer model (MMTV-neu), IL-1R8-deficiency reduced tumor growth and metastasis 
and was associated with increased mobilization and activation of immune cells, such 
as NK cells and CD8+ T cells. Finally, immune-gene signature analysis in clinical 
specimens revealed that high IL-1R8 expression is associated with impaired innate 
immune sensing and T-cell exclusion from the tumor microenvironment. Our results 
indicate that high IL-1R8 expression acts as a novel immunomodulatory mechanism 
leading to dysregulated immunity with important implications for breast cancer 
immunotherapy.
INTRODUCTION
During tumorigenesis, cancer cells interact with the 
immune system and modify the tumor microenvironment 
(TME) to subvert the host immune response [1, 2]. In 
advanced tumors, the immune balance is tilted towards 
pro-tumor inflammation and local dysregulation of the 
innate and adaptive immune response [3]. Inflammatory 
signals derived from tumor cells, stromal cells and 
immune cells act as critical factors regulating qualitative 
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and quantitatively pro-tumoral inflammation and 
antitumor immunity during the cancer-immunity cycle [3]. 
This complex crosstalk has been recognized as a hallmark 
of cancer [4], and understanding the molecular pathways 
involved in the induction of pro-tumoral inflammation and 
immune evasion could enable the development of new 
therapies and improve the efficacy of existing ones. 
The activation of Interleukin-1 (IL-1) receptor family 
members (ILRs) and Toll-like receptors (TLRs) represents 
a critical early innate immune sensing event promoting 
immunosurveillance and antitumor immunity [5–7]. ILRs 
and TLRs activation ignites a signal transduction cascade 
with pro-inflammatory outcomes, including the activation 
of NF-κB and the secretion of pro-inflammatory cytokines 
such as Type I IFNs and TNFα, which are in turn necessary 
for natural killer (NK) and dendritic cell (DC) activation, 
together with CD8+ T cell priming against tumor antigens 
and trafficking into the TME [8–10]. Therefore, ILRs and 
TLRs activation plays an important role in inflammation, 
initiation and amplification of innate immunity and 
orientation of adaptive immunity [11, 12]. 
IL-1R8 is a member of the ILRs family. IL-1R8 
negatively regulates signaling from IL-1R1, IL-18R, 
ST2 and a number of TLRs [13, 14] by acting as a decoy 
receptor for key components of the MyD88 signaling 
cascade, such as IRAK and TRAF6 and by interfering 
with ILRs dimerization through its Ig domain [13–15]. 
Recently, it has been demonstrated that, in humans, IL-
1R8 can also bind to IL-37, an anti-inflammatory cytokine 
induced by TLRs and cytokines and a natural suppressor 
of innate inflammatory response [16, 17]. Curiously, no 
IL-37 homologue has been identified in mice wherein. 
Irrespectively of its mode of action, IL-1R8 acts as 
a brake for pro-inflammatory signals, and its expression 
is essential for regulating the detrimental effects of innate 
and adaptive immune responses in pathologic conditions 
such as infections, sepsis, chronic inflammation and 
autoimmune disease [18–21]. In addition, IL-1R8-
deficiency in mice results in more severe gut inflammation 
during dextran sulfate sodium colitis [22, 23], increased 
susceptibility to colitis-associated colorectal cancer 
[23–25], and more severe and earlier onset of monoclonal 
B cell expansions in a murine model of chronic 
lymphocytic leukemia (CLL) [26]. 
In this study, we show that IL-1R8 is up-regulated 
during breast epithelial cell transformation and in 
primary breast tumors. Using clinical samples and 
in vitro and in vivo experiments, we also demonstrate that 
high expression of IL-1R8 in breast tumors modulates 
the expression of inflammatory mediators in the TME, 
affecting the mobilization and activation of immune cells 
and fostering tumor growth and metastasis. Collectively, 
our findings indicate that expression of IL-1R8 represents 
a novel immunomodulatory mechanism leading to 
impaired innate immune sensing and antitumor immunity 
and provides new insights to cancer immunotherapy.
RESULTS
IL-1R8 is up-regulated in transformed breast 
epithelial cells and in primary breast tumors
IL-1R8 was identified as an up-regulated gene in 
transformed breast epithelial cells by comparing gene 
expression profiles from a parental, non-transformed, 
conditionally immortalized human mammary luminal 
epithelial cell line (HB4a), and a HER2 overexpressing 
variant (HB4a-C5.2, designated HB4aHER2+ for the purpose 
of this work) [27]. Transcriptional changes associated 
with breast epithelial cell transformation were measured 
using Massively Parallel Signature Sequencing (MPSS) 
and IL-1R8 ranked among the top 50 differentially 
expressed genes (unpublished results). Reliable MPSS tags 
(5ʹGATCATAGGGACAGCGG3’) assigned to IL-1R8 were 
more frequently found in the HB4aHER2+ library than in the 
HB4a library (36 tpm vs. 4 tpm, P < 0.001), indicating that 
IL-1R8 gene expression is up-regulated in the transformed 
breast epithelial cells. IL-1R8 differential expression in the 
HB4aHER2+ variant was confirmed both at the mRNA and 
protein levels. A 4-fold induction of IL-1R8 mRNA and a 
2-fold induction of IL-1R8 protein expression were observed 
in HB4aHER2+ cells when compared to HB4a (Figure 1A). 
IL-1R8 up-regulation in primary breast tumors was 
confirmed by analyzing RNA-seq expression data obtained 
from The Cancer Genome Atlas (TCGA). We observed 
that IL-1R8 gene expression is significantly higher in 
primary breast tumors compared to normal breast tissue 
(median 701.1 vs. 358.8 RSEM normalized expression 
values, P < 0.0001, Figure 1B) and higher levels of IL-
1R8 mRNA were observed across all molecular breast 
cancer subtypes, except in the basal-like breast cancer 
subtype (HER2+ subtype median 563.4 RSEM normalized 
expression values, P = 1.13e-05, Luminal A subtype median 
830.2 RSEM normalized expression values, P < 2.2e-16, 
Luminal B median 823.9 normalized expression values, 
P < 2.2e-16 and basal-like subtype median 360.9 
normalized expression values, P = 0.83) (Figure 1B).
Collectively, these results indicate that IL-1R8 is up-
regulated during breast epithelial cell transformation and 
across all molecular breast cancer subtypes, except in the 
basal-like subtype. 
IL-1R8 up-regulation in transformed breast 
epithelial cells fine-tunes IL-1-dependent 
NF-κB activation and the expression of pro-
inflammatory cytokines
IL-1R8 negatively regulates the innate inflammatory 
response by acting as a decoy receptor for TLRs and 
ILRs signaling. NF-κB activation and the production 
of pro-inflammatory cytokines are important endpoints 
of TLR and IL-1R family signaling [28]. Gene transfer 
experiments have shown that IL-1R8 up-regulation inhibits 
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NF-κB activation and the production of pro-inflammatory 
cytokines in HeLa and hepG2 cells after exposure to IL-1 
and TLR ligands [14]. Therefore, to address the role of IL-
1R8 up-regulation in transformed breast epithelial cells, we 
treated HB4a and HB4aHER2+ cells with IL-1β and analyzed 
IκB expression levels and NF-κB activation by Western blot 
and EMSA, respectively. IκB is negative regulator of NF-
κB and is phosphorylated by specific kinases in response 
to inflammatory signals. The phosphorylated IκB protein 
is then ubiquitinated and degraded leading to a decrease in 
IκB expression levels and to NF-κB activation. As expected, 
IκB expression decreases shortly after IL-1β treatment 
in both cell lines, but the decrease was less pronounced 
in HB4aHER2+ cells compared to HB4a (Figure 1C). To 
verify if the observed differences in IκB expression levels 
were due to IL-1R8 up-regulation in HB4aHER2+ cells, we 
generated HB4aHER2+ cell variants stably expressing IL-
1R8 shRNAs (HB4aHER2+/IL1R8KD) (Supplementary Figure 1). 
No differences in the growth rate between HB4aHER2+ and 
HB4aHER2+/IL1R8KD cells studied herein were observed and 
IL-1R8 knockdown remained stable during the course of 
this work (data not shown). After IL-1R8 knockdown, the 
differences in IκB expression levels observed between 
HB4a and HB4aHER2+ disappeared (Figure 1C). In addition, 
NF-κB activation was significantly enhanced in HB4aHER2+/
IL1R8KD cells compared to HB4aHER2+ cells (Figure 1D). 
Gene-expression of different pro-inflammatory 
cytokines in HB4a and HB4aHER2+ cells was then analyzed 
after stimulation with IL-1β. Shortly after stimulation, a 
significant increase in IL-6, IL-8, CSF2, CSF3, IFN-β1 
and TNFα expression was observed in both cell lines, 
although the induction of these inflammatory mediators 
was significantly lower in HB4aHER2+cells compared to 
HB4a cells. Noteworthy, IL-1R8 knockdown in HB4aHER2+ 
cells reverted the expression of these cytokines after IL-1β 
stimulation to the levels observed in parental HB4a cells 
(Figure 1E). 
Taken together, these results indicate that IL-
1R8 up-regulation in transformed breast epithelial cells 
attenuates IL-1-dependent NF-κB activation and the 
expression of pro-inflammatory cytokines.
IL-1R8 deficiency in a transgenic mouse model 
of breast cancer delays tumor onset and reduces 
tumor burden and metastasis
To further investigate the role of IL-1R8 in breast 
tumor formation and progression, IL-1R8 knock-out 
Figure 1: Up-regulation of IL-1R8 expression inhibits IL-1-dependent NF-κB activation and expression of pro-
inflammatory cytokines in HER2-transformed breast cells. (A) IL-1R8 protein expression by western-blot (upper part) and 
mRNA relative expression by qRT-PCR (lower part) in HB4a and HB4aHER2+ epithelial mammary cell lines. **P = 0.002, unpaired Student’s 
t-test. (B) On the left, IL-1R8 normalized expression values in normal mammary tissue (n = 113) compared to primary breast tumors 
(n = 792); on the right, normal mammary tissue compared to Basal-like (n = 136), HER2+ (n = 65), Luminal A (n = 415) and Luminal 
B (n = 176) molecular breast cancer subtypes using RNA-seq data obtained from TCGA. a) P = 0.8, b) P = 1.1e-08, c) P = 2.2e-16, d) 
P = 2.2e-16, Wilcoxon rank-sum`s test. Data is shown as the group median value in RSEM normalized expression ± interquartile range. 
(C) Protein levels of IκB and β-Tubulin by Western-blot in HB4a, HB4aHER2+ and HB4aHER2+/IL1R8KD cells stimulated or not with 5 ng/mL 
of IL-1β for 15 minutes (D) Electromobility shift assay (EMSA) for NF-κB of nuclear extracts of cells stimulated or not with IL-1β 5 ng/
mL for 24 hours. Arrow indicates the position of NF-κB complex; FP: Free probe. Right panel: densitometry analysis of band intensity. 
(E) Cytokines expression of HB4a, HB4aHER2+ and HB4aHER2+/IL1R8KD cells stimulated with IL-1β 5 ng/mL for 1 hour by qRT-PCR. Values 
represent expression relative to non-treated cells. Error bars indicate the variation between the means of three independent experiments. 
Unpaired Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.0001, NS: not significant. 
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mice (IL-1R8−/−) were crossed with a transgenic model of 
spontaneous breast tumorigenesis (MMTV-neu), to generate 
MMTV-neu/IL-1R8−/− mice. The presence and absence 
of IL-1R8 expression in tumors from MMTV-neu/IL-
1R8+/+ and MMTV-neu/IL-1R8−/− mice, respectively, were 
confirmed by immunohistochemistry (IHC) and, in tumors 
from MMTV-neu/IL-1R8+/+ animals, IL-1R8 expression 
was predominantly detected in the tumor cells (Figure 2A). 
Significant differences in tumor onset, incidence and 
burden were observed between the two groups of animals. 
As shown in Figure 2B, MMTV-neu/IL-1R8−/− mice 
presented later tumor onset compared to MMTV-neu/IL-
1R8+/+ mice. By week 24, 65% (24/37) of the animals in 
the MMTV-neu/IL-1R8−/− group developed breast tumors 
compared to 95% (26/27) in the group of MMTV-neu/IL-
1R8+/+ mice (P = 0.0003). In addition, at week 24, the mean 
number of mammary tumors per animal was significantly 
lower in the MMTV-neu/IL-1R8−/− group as compared to 
the MMTV-neu/IL-1R8+/+ group (2 vs. 4 tumors/animal, 
P = 0.007, Figure 2C). Moreover, by week 24, tumors 
from MMTV-neu/IL-1R8−/− mice were 3 times smaller than 
tumors from MMTV-neu/IL-1R8+/+ mice (351 vs. 1173 mm3, 
P = 0.02, Figure 2D). Finally, by week 30, the number of 
metastatic lesions in the lungs of MMTV-neu/IL-1R8−/− 
mice was significantly lower than in MMTV-neu/IL-1R8+/+ 
animals (0.7 vs. 8.4 lesions/mouse, P = 0.03, Figure 2E). 
Bone marrow chimeras were then used to assess 
the relative importance of IL-1R8 expression in the non-
hematopoietic/tumor cells in the reduced tumor burden 
and growth observed in MMTV-neu/IL-1R8−/−mice. No 
significant differences in tumor onset, incidence and 
burden were observed when MMTV-neu/IL-1R8−/−mice 
were transplanted with IL-1R8+/+ bone-marrow cells, 
supporting an important role for IL-1R8 expression by 
non-hematopoietic/tumor cells during breast tumorigenesis 
(Supplementary Figure 3).
In addition to the differences observed in tumor 
growth and burden, tumors from MMTV-neu/IL-1R8−/−
mice and MMTV-neu/IL-1R8+/+ mice displayed different 
histopathological characteristics. By week 24, tumors from 
MMTV-neu/IL-1R8−/−mice displayed fewer aggressive 
features, such as tissue necrosis and cellular atypia, although 
no difference was observed in the number of mitosis per 
field when compared to MMTV-neu/IL-1R8+/+ tumors (1.2 
vs 2.4 mitosis/field, P = 0.22, Supplementary Table 1). 
Furthermore, MMTV-neu/IL-1R8−/−tumors exhibited an 
expansive growth pattern (100% vs 33%) while MMTV-
neu/IL-1R8+/+ tumors were more infiltrative (66% vs 0%, 
P = 0.06, Supplementary Table 1 and Figure 2F). 
These results reveal that IL-1R8 expression in breast 
tumor cells contributes to tumor formation, progression 
and metastatic dissemination.
IL-1R8-deficiency in a transgenic mouse model 
of breast cancer promotes the mobilization and 
skews the activation of immune cells
Pro-inflammatory cytokines are critical factors 
regulating the mobilization and activity of immune cells 
in the TME [3]. Since IL-1R8 can negatively modulate the 
Figure 2: IL-1R8-deficiency delays tumor development and reduces tumor burden in a transgenic MMTV-neu animal 
model. (A) IHC staining of IL-1R8 in mammary tumors from MMTV-neu/IL-1R8+/+ and MMTV-neu/IL-1R8−/− mice. Scale bar: 50 µM. 
(B) Kaplan–Meier analysis of tumor-free survival of MMTV-neu/IL-1R8+/+ (n = 27) and MMTV-neu/IL-1R8−/− (n = 37) mice. Log-rank 
test, P = 0.0003. (C) Average number of mammary tumors per mouse over time (weeks). *P < 0.05 and **P < 0.01, unpaired Student’s 
t-test. (D) Average total tumor volume per mouse over time (weeks). *P = 0.024, paired Student’s t-test. (E) Number of lung metastatic 
lesions per mouse at 30 weeks of age, Mann-Whitney test. Left panel, dotted line reveals regions of metastatic lesions. Scale bar: 50 µM. 
*P = 0.024. (F) Hematoxylin and eosin (HE) staining of mammary tumors from 24-weeks old mice revealing distinct growth and invasive 
features. MMTV-neu/IL-1R8+/+ infiltrative growth pattern (dotted line) and MMTV-neu/IL-1R8−/− expansive growth pattern (dotted line). 
Scale bar: 200 µM. 
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expression of inflammatory mediators in IL-1R-stimulated 
transformed breast epithelial cells in vitro, we sought to 
analyze its role on the immune composition in vivo using 
our transgenic mouse model of breast cancer.
Although the total number of tumor-infiltrating 
leukocytes (CD45+ cells) from mice at 24-weeks of age 
was found to be lower in MMTV-neu/IL-1R8−/− tumors 
(IRA 1.2 ± 0.2 vs. 2.4 ± 0.4, P = 0.02, Supplementary 
Figure 4A), these tumors presented a significantly 
higher proportion of DCs (11.4 ± 1.6 vs. 6.8 ± 1.2 F4/80-
CD11c+/CD45+ cells, P = 0.04) and NK cells (2.7 ± 0.5 
vs. 0.8 ± 0.2 CD3-CD49b+/CD45+ cells, P = 0.01) and 
a lower proportion of Tumor Associated Macrophages 
(TAMs) (37.6 ± 7.7 vs. 65.9 ± 8.3 CD11b+F4/80+/CD45+ 
cells, P = 0.03) compared to MMTV-neu/IL-1R8+/+ tumors 
(Figure 3A and Supplementary Figures 4B, 5). A marginal 
difference in the percentage of immature macrophages 
(3.6 ± 0.8 vs. 9.4 ± 2.4 CD11b+F4/80+Ly6C+ cells/
Macrophages, P = 0.052, Supplementary Figure 4A) was 
also observed between MMTV-neu/IL-1R8−/− and MMTV-
neu/IL-1R8+/+ tumors, but no significant differences in the 
proportion of infiltrating polymorphonuclear cells (PMN) 
(CD11b+Ly6G+/CD45+ cells, P = 0.9, Supplementary 
Figure 4B), B cells (CD19+/CD45+ cells, P = 0.6, 
Supplementary Figure 4C) or T cells (14.3 ± 3.9 vs. 18.7 ± 
5.5 CD3+/CD45+ cells, P = 0.5, Supplementary Figure 4D) 
were observed between both types of tumors. 
It is well known that the outcome of an immune 
response towards a tumor is largely determined by the 
type of immune response elicited and a tumor-directed 
immune response, involving NK cells and cytotoxic CD8+ 
T cells is known to protect against tumor development and 
progression [29]. NK cells constitutively express a lytic 
machinery capable of killing target cells independently 
of antigen presentation [30]. In addition to the higher 
proportion of NK cells observed in MMTV-neu/IL-
1R8−/− tumors, we found that these cells were also more 
mature (52.9 ± 4.4 vs. 35.2 ± 4 CD11b+ cells/NK cells, 
P = 0.02, Figure 3B). To further investigate whether IL-
1R8 up-regulation in tumor cells could modulate NK 
cell activation, NKL cells were cultured in the presence 
of either HB4aHER2+ or HB4aHER2+/IL1R8KD cells and IFN-γ 
levels in the culture supernatant were used as a surrogate 
marker of NK cell activation. Higher IFN-γ levels were 
detected in supernatants of NKL cells co-cultured with 
HB4aHER2+/IL1R8KD as compared to HB4aHER2+ (65.9 ± 10.4 
vs. 31.8 ± 7.7 pg/mL, P = 0.03) (Figure 3C), indicating 
that high IL-1R8 expression in tumors cells can potentially 
inhibit NK cell activation. 
Besides NK cells, tumor infiltrating lymphocytes 
(TILs) also play and important role in tumor cell 
elimination and the presence of TILs in tumor biopsies, 
in particular of cytotoxic CD8+ T cells, is emerging as 
an independent positive prognostic factor in different 
solid tumors, including breast cancer [31]. Although we 
did not observe significant differences in the proportion 
of infiltrating T cells between MMTV-neu/IL-1R8−/− and 
MMTV-neu/IL-1R8+/+ tumors Supplementary Figure 5D, 
MMTV-neu/IL-1R8−/− tumors presented a significantly 
lower infiltrate of CD4+ T cells (47.9 ± 3.7 vs. 63.2 ± 5.1 
CD4+/CD3+, P = 0.04) and higher infiltrate of CD8+ T cells 
(38.5 ± 3 vs. 23.7 ± 4.9 CD8+/CD3+, P = 0.02), with a 
higher CD8+/CD4+ T cell ratio (0.9 ± 0.1 vs. 0.4 ± 0.1, 
P = 0.02, Figure 3D), suggesting that IL-1R8 expression 
by tumors cells reduces the effective mobilization of CD8+ 
T cells into the TME. 
We also analyzed tumors of equivalent sizes (tumor 
volume of 500 mm3), to evaluate whether the differences 
in the immune infiltrate could be due to different tumor 
sizes. As shown in Figure 3E, MMTV-neu/IL-1R8−/− mice 
developed 500 mm3 tumors at later points compared to 
MMTV-neu/IL-1R8+/+ mice (Median of 34 vs. 29 weeks, 
P = 0.003). Notably, a higher percentage of DCs (14.7 ± 
2.1 vs. 8.8 ± 1.8 F4/80-CD11c+/CD45+ cells, P = 0.04, 
Figure 3F) as well as a higher CD8+/CD4+ T cell ratio (0.8 
± 0.1 vs. 0.4 ± 0.1, P = 0.01, Figure 3G) was still observed 
in MMTV-neu/IL-1R8−/− tumors. However, in contrast 
to tumors collected at 24-weeks, we did not observe 
significant differences in the percentage of infiltrating 
TAMs, T cells or NK cells between the tumors (Figure 3F) 
although a larger population of mature NK cells (42.3 ± 
4.4 vs. 28.5 ± 2.5 CD11b+NK cell/total NK cells, P = 0.02, 
Figure 3H) was observed in MMTV-neu/IL-1R8−/− tumors. 
Since TAMs are known to generally present a pro-
tumoral M2-like phenotype [32], we next characterized 
the phenotype of tumor-infiltrating myeloid cells 
from MMTV-neu/IL-1R8−/− and MMTV-neu/IL-1R8+/+ 
tumors of the same size, looking at classic M1 and M2 
polarization markers [33]. After purification of CD11b+/
Ly6G- cells, MHCIIhigh (CD11b+/Ly6C-/MHCIIhigh) and 
MHCIIlow (CD11b+/Ly6C-/MHCIIlow) TAMs were sorted 
to > 98% purity to analyze the expression of M1-like 
and M2-like markers (Supplementary Figure 6) [33]. 
As shown in Figure 4A, both MHCIIhigh and MHCIIlow 
population of TAMs from MMTV-neu/IL-1R8−/− tumors 
displayed lower levels of M2-like markers (CD206, Ym1, 
TNFα, STAB1, IL-10) compared to TAMs from MMTV-
neu/IL-1R8+/+ tumors. To further investigate if IL-1R8 
expression in tumor cells could induce M2-macrophage 
polarization, THP-1 macrophage-like cells [34] were 
cultured in the presence of conditioned medium from 
IL-1β-stimulated HB4aHER2+ and HB4aHER2+/IL1R8KD cells. 
THP-1 macrophage-like cells cultured with conditioned 
medium from HB4aHER2+ expressed significantly higher 
levels of the mannose receptor M2-like marker CD206 
(Mean Fluorescence Intensity (MFI) 2,551 ± 43 vs. 
1,135 ± 11, P = 0.034) and lower levels of the T cell 
co-stimulatory M1-like marker CD86 (MFI 936 ± 38 vs. 
3,157 ± 472, P = 0.009) as compared to HB4aHER2+/IL1R8KD 
cells (Figure 4B and 4C), indicating that high IL-1R8 
expression can skew macrophage polarization towards an 
M2-like phenotype. 
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We finally compared the intratumoral levels of 
different cytokines in homogenates from MMTV-neu/IL-
1R8−/− and MMTV-neu/IL-1R8+/+ tumors (Supplementary 
Figure 7). At 24-weeks, MMTV-neu/IL-1R8−/− tumors 
presented lower intratumoral levels of IL-1β (273.2 ± 56 
vs 667.6 ± 165 pg/mg, P = 0.02) and of pro-angiogenic 
vascular endothelial growth factor (VEGF) (152.5 ± 
10.3 vs 279.7 ± 37.5 pg/mg, P = 0.004), but higher 
levels of IFN-γ (50.2 ± 8.6 vs 27.8 ± 4 pg/mg, P = 0.04). 
Accordingly, high intratumoral levels of IL-1β were 
recently shown to activate endothelial cells to produce 
VEGF and IL-1β inhibition stably reduced tumor growth 
by limiting inflammation and inducing the maturation of 
immature myeloid cells into M1 macrophages [35].
Figure 3: IL-1R8-deficiency promotes a protective tumor immune infiltrate in MMTV-neu mice. Leukocyte infiltrate 
analysis by FACS: (A) DCs (CD11b+F4/80-CD11c+), Natural-Killer cells (CD3-CD49b+), Macrophages (CD11b+F4/80+) and (B) Mature 
NK cell population (CD11b+CD49b+/Total NK cells). (C) IFN-γ levels determined by ELISA in the supernatants of NKL cells, HB4aHER2+ 
or HB4aHER2+/IL1R8KD cells cultured separately or in co-culture with NKL cells (beige background). (D) FACS analysis of CD4+ and CD8+ T 
cells. Results are presented as % of CD3+ cells (left panel) or as ratio of CD8+ and CD4+ T cells (right panel). (E) Kaplan–Meier analysis of 
the incidence of tumors reaching 500 mm3 volume in MMTV-neu/IL-1R8+/+ (n = 8) and MMTV-neu/IL-1R8−/− (n = 10) mice. P = 0.0035, 
Log-rank test. (F) FACS analysis of TAMs (CD11b+F4/80+), DCs (CD11b+F4/80-CD11c+), T-Cells (CD3+) and NK cells (CD3-CD49b+). 
Results are presented as % of CD45+ cells. (G) Ratio of CD8+/CD4+ T cells. (H) Mature NK cell population (CD11b+CD49b+/Total NK 
cells). Error bars indicate the variation between the means of three independent experiments. *P < 0.05, unpaired Student’s t-test. 
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Collectively, our results suggest that IL-1R8 
expression in breast tumors plays a critical role in 
the maintenance of a local pro-tumoral inflammatory 
microenvironment and prevents the development of 
protective immunity.
IL-1R8 expression in clinical samples is 
associated with impaired mobilization of NK, DC 
and CD8+ T cells
The relative abundance of tumor-infiltrating 
leukocytes in clinical samples can be indirectly quantified 
by measuring intratumoral transcript levels of coordinately 
expressed immune cell-specific genes (immune 
metagenes) [36]. To determine the clinical relevance 
of our in vivo and in vitro findings, we analyzed RNA-
seq expression data from 1102 primary breast tumors, 
including all four major molecular subtypes obtained from 
TCGA. Breast tumors were classified according to IL-1R8 
expression levels irrespectively of their molecular subtype 
(see Materials and Methods) and were analyzed for the 
expression of immune metagenes.
In accordance with our findings, lower expression 
levels of T cell metagenes (CD28, CD3G, CD8A, CD8B, 
FYB, ICOS, LCP2, LTA) and of different chemokines 
associated with CD8+ T cell recruitment (CCL2, CCL3, 
CCL4, CCL5, CXCL9 and CXCL10) were observed 
among breast tumors expressing higher levels of IL-
1R8 (IL-1R8 high tumors, Table 1). Furthermore, lower 
expression levels of T cell co-stimulatory markers (CD80, 
CD86), of DC metagenes and of components of the 
peptide-presenting machinery (HLA-DMA, HLA-DMB, 
Figure 4: IL-1R8 expression modulates the polarization state of TAMs in mammary tumors. (A) Analysis by qRT-PCR of 
selected M1 and M2-like markers of MHChigh and MHClow tumor-associated macrophages (TAMs), infiltrating mammary tumors in MMTV-
neu/IL-1R8+/+ (n = 4) and MMTV-neu/IL-1R8−/− (n = 4) mice (mean ± SEM). Data were relative to 18S expression and normalized versus 
the mean of wild-type and expressed as mean ± SEM. (B) FACS histograms and (C) Mean Fluorescence Intensity (MFI) showing M1-
like marker CD86 and M2-like marker CD206 expression in THP-1 macrophage-like cells after incubation with IL-4 30 ng/mL (M2-like 
polarization control), LPS 25 ng/mL (M1-like polarization control) or HB4aHER2+ and HB4aHER2+/IL1R8KD conditioned medium (CM) for 24 
hours. (A–C) Error bars indicate the variation between the means of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, 
unpaired Student’s t-test.
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HLA-DOA and HLA-DOB) were also observed in IL-
1R8 high tumors (Supplementary Table 2). Finally, lower 
levels of several pro-inflammatory cytokines (IL1B, IL10, 
IL12, IL6, IL8, TNF), NK cell metagenes (NCR1, XCL1), 
cytolytic enzymes (GZMA, GZMB, PRF) and type I IFN-
induced genes were also observed in IL-1R8 high breast 
tumors (Table 1 and Supplementary Table 2). 
A similar analysis was carried out after classifying 
primary breast tumors according to their molecular 
subtype. Lower expression levels for most of these 
immune metagenes were also observed in IL-1R8 high 
luminal A and B molecular subtypes. However, clear 
differences in the expression level for these immune 
metagenes were not observed for IL-1R8 high Her2+ and 
basal-like tumors, possibly due to a small sample size in 
the case of Her2+ tumors (n = 65) and to the lack of IL-
1R8 up-regulation in basal-like tumors (Supplementary 
Tables 3–6). 
These results corroborate our in vivo and in vitro 
observations and indicate that high IL-1R8 expression in 
primary human breast tumors is associated with a skewed 
inflammatory response and impairment in the mobilization 
of protective leukocytes in the TME.
IL-1R8 expression in clinical samples is 
associated with a non-T cell- inflamed TME
Solid tumors can be classified into two broad categories 
according to cellular and molecular characteristics of the 
TME [37]. T cell–inflamed tumors are characterized by a 
spontaneous T cell infiltrate, a broad chemokine profile, which 
supports influx of CD8+ effector T cells, and a type I IFN 
Table 1: Expression levels of immune-related genes in IL-1R8-high and IL-1R8-low primary breast 
tumors
IL-1R8 High IL-1R8 Low adj-P
T-Cell transcripts
CD28 43.3 63.5 1.3E-08
CD3G 16.2 31.0 1.6E-09
CD8A 138.5 171.7 1.5E-02
CD8B 35.1 49.6 7.4E-04
FYB 314.8 484.6 7.0E-15
ICOS 15.2 28.8 1.6E-09
LCP2 290.8 397.3 5.2E-10
LTA 9.0 12.0 3.9E-05
CD8+ T-cell Chemokines
CCL2 290.0 413.1 7.0E-08
CCL3 85.4 102.2 1.7E-03
CCL4 72.9 99.5 2.6E-08
CCL5 441.4 577.3 1.9E-03
CXCL9 475.2 977.6 2.1E-09
CXCL10 314.5 571.5 9.1E-12
IFN-induced genes
EIF2AK2 438.5 624.1 1.8E-23
GBP1 713.7 1258.3 1.8E-23
IFI16 1402.9 2043.8 3.2E-21
IFIH1 630.9 843.3 1.7E-10
MX2 385.0 513.1 3.2E-07
OAS2 1337.9 1707.1 1.4E-03
PLSCR1 680.7 875.4 4.8E-12
RSAD2 382.7 575.8 3.7E-08
STAT1 4762.1 6824.6 8.9E-12
STAT2 2027.1 2285.4 2.2E-06
TAP1 2043.3 2400.8 1.1E-03
TRAIL 2714.6 3246.5 3.0E-02
TRAILR2 690.4 785.0 1.1E-05
XAF1 709.0 847.2 1.3E-02
Oncotarget9www.impactjournals.com/oncotarget
signature indicative of innate immune activation. In contrast, 
non-T cell-inflamed tumors lack all these characteristics 
and present an immunosuppressive microenvironment that 
inhibits the activation of antigen presenting cells and the 
priming and trafficking of effector T cells [37, 38]. 
Immune gene signatures based on the expression of 
T cell specific markers, different chemokines associated 
with CD8+ T cell recruitment [39] and IFN-induced genes 
have also been used to classify tumors according to their 
T cell-inflamed phenotype. Since IL-1R8 expressing 
MMTV-neu mammary tumors present a lower infiltration 
CD8+ T cells and lower levels of intratumoral IFN-γ, 
we used immune gene signature analysis to investigate 
whether IL-1R8 expression was associated with a non-T 
cell-inflamed TME in clinical samples. 
Accordingly, 1,102 primary breast tumors including 
all major molecular subtypes, were classified into those 
with a non-T cell-inflamed and those with T cell-inflamed 
phenotype based of the expression level of T cell specific 
markers (FYB, LCP2, CD3E, CD8A, CD28), different 
chemokines associated with CD8+ T cell recruitment 
(CCL5, CCl2, CCl3, CCL4, CXCL9, CXCL10) and 
IFN-induced genes (IFI16, IFIH1, GBP1, OAS2, MX1). 
Approximately, 64% of all breast tumors expressed lower 
expression levels of the 16 T-cell inflamed signature genes 
(709/1,102) and, noteworthy, the majority of IL-1R8 high 
tumors were clustered in the group of tumors expressing 
lower levels of T-cell inflamed signature genes (394/551, 
72%, P = 6.758e-07, Figure 5A). In addition, a significant 
inverse correlation between IL-1R8 expression and the 
expression of all, except one, T cell signature genes was 
observed (Figure 5B), indicating that IL-1R8 expression 
is associated with a non-T cell-inflamed TME in breast 
tumors. 
A similar analysis was carried out after classifying 
primary breast tumors according to their molecular 
subtype. Lower expression levels for most of these T cell 
signature genes were also observed for in IL-1R8 high 
luminal A and B molecular subtypes. However, clear 
differences in the expression level for these immune 
Figure 5: High IL-1R8 expression is associated with a non-T cell inflamed molecular signature in primary breast 
tumors. (A) Heat map of 1,102 primary breast tumors clustered in T cell (N = 393) and non-T cell (N = 709) inflamed groups based on the 
expression of T cell specific markers (FYB, LCP2, CD3E, CD8A, CD28), different chemokines associated with CD8+ T cell recruitment 
(CCL5, CCl2, CCl3, CCL4, CXCL9, CXCL10) and IFN-induced genes (IFI16, IFIH1, GBP1, OAS2, MX1). The non-T-cell inflamed 
cluster is enriched for IL-1R8-high tumors (394/551 or 72%, Chi-square test P = 6.758e-07). (B) Correlation between IL-1R8 expression 
and the expression of the 16 genes from the T-cell inflamed signature. Color scale represents Spearman’s rho coefficient. 
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metagenes were not observed for IL-1R8 high Her2+ and 
basal-like tumors, possibly due to a small sample size in 
the case of Her2+ tumors (n = 65) and to the lack of IL-
1R8 up-regulation in basal-like tumors (Supplementary 
Figure 8). 
Altogether, these results indicate that high IL-1R8 
expression in human breast tumors is associated with 
a non-T cell inflamed phenotype and may represent a 
new immune escape mechanism contributing to T cell 
exclusion and impaired antitumor immunity in this class 
of tumors.
DISCUSSION
The activation of innate immune sensors, such 
as ILRs and TLRs, is an essential mechanism of sterile 
immunity, playing a critical role in the promotion 
of pro-tumoral inflammation and mediation of 
immunosurveillance [10,40]. Therefore, molecules that 
negatively regulate their signaling may be exploited by 
tumors to induce immune tolerance and mitigate host 
antitumor immune response. Here, we demonstrated for 
the first time that IL-1R8, a negative regulator of pro-
inflammatory signals, is up-regulated in transformed 
breast epithelial cells and in HER2+ and luminal primary 
breast cancer molecular subtypes. Most importantly, 
we demonstrated that its expression contributes to an 
impaired innate immune sensing and the development of 
an antitumor immune response. 
IL-1R8 negatively regulates ILRs and TLRs 
signaling by acting as a decoy receptor and by interfering 
with ILRs dimerization through its Ig domain [13–15]. 
Recently, it has been demonstrated that, in humans, 
IL-1R8 can also bind to IL-37, an anti-inflammatory 
cytokine induced by TLRs and cytokines and a natural 
suppressor of innate inflammatory response [16, 17]. The 
binding produces the formation of the tripartite complex 
involving IL-37/IL-18Rα/IL-1R8, which is necessary 
for the activation of an anti-inflammatory response. 
Therefore, in humans, IL-1R8 negatively regulates the 
innate inflammatory response by acting both as a decoy 
for TLRs and ILRs signaling and as a co-receptor for IL-
37 in the activation of an anti-inflammatory program. In 
the present work, we have primarily explored the role of 
IL-1R8 up-regulation in the modulation of ILRs and TLRs 
signaling. Further studies will be necessary to properly 
evaluate the implications of IL-37 and IL-1R8 interaction 
in cancer biology. 
IL-1R8 has been previously shown to act as a decoy 
receptor for ILRs and TLRs in human colon and bladder 
epithelial cells [23,41]. In the present work we confirmed 
IL-1R8 decoy activity in human breast epithelial cells. 
Using a mammary epithelial cancer cell model, we showed 
that IL-1R8 expression in transformed cells fine-tuned IL-
1-dependent NF-κB activity and the expression of several 
pro-inflammatory cytokines, including some involved in 
macrophage polarization (CSF2, IFN-β1 and TNFα) and 
NK cell activation (IFN-β1 and TNFα) [42–44]. Indeed, 
using co-culture experiments, we observed that IL-1R8 
expression in transformed cells skews macrophage and 
NK cell activation in vitro. 
Furthermore, using a murine breast cancer model, 
we showed that MMTV-neu/IL-1R8+/+ mammary 
tumors grew faster and were more metastatic compared 
to MMTV-neu/IL-1R8−/− tumors. Although HER2 
overexpression is sufficient to drive mammary lesions 
in MMTV-neu animals, the pace of tumor progression 
is known to be significantly influenced by tumor-elicited 
mechanisms of immunosuppression [45, 46]. In line 
with this evidence, there was a significant increase of 
tumor-infiltrating leukocytes associated with antitumor 
immunity, including mature NK cells, DCs and CD8+ T 
cells, in MMTV-neu/IL-1R8−/− mice. 
Our in vivo results however are in contrast with 
those obtained with colitis-associated colon-cancer models 
and lymphocytic leukemia where IL-1R8 has been shown 
to play a tumor-suppressive role [24–26]. In addition, the 
aberrant expression of an IL-1R8 splicing isoform, with 
dominant-negative function in colon tumors, has been 
recently shown to promote inflammation and colitis-
associated colon cancer in mouse and humans [47]. The 
dual role of inflammation in cancer is well known and 
several lines of evidence indicate that inflammatory and 
immune mechanisms in cancer are tissue- and organ 
specific [48,49]. Therefore, it is not surprising that IL-
1R8 can act as a tumor suppressor in models of cancer 
strongly dependent on inflammation, while having a tumor 
promoting effect by fine-tuning inflammation and avoiding 
detection and eradication by the immune system in other 
tumor types. In line with our results, IL-1R8 up-regulation 
in prostate cancer has been recently associated with worse 
prognosis and can predict biochemical recurrence after 
prostatectomy in low-grade prostate cancer patients [50].
In accordance with our in vitro experiments using 
IL-1R8-knockdown cancer cells, we observed that 
MMTV-neu/IL-1R8−/− TAMs showed reduced expression 
of markers associated with an M2-like phenotype, in 
particular CD206, YM1, IL-10 [43]. TAMs usually acquire 
a skewed M2-like phenotype oriented to tumor promotion 
and it has been reported that Th2 CD4+ T cells promote 
breast tumor progression and metastasis by educating 
TAMs to produce pro-angiogenic and pro-metastatic 
factors [51]. Therefore, the results showing that M1-
macrophage polarization, directly induced by MMTV-
neu/IL-1R8−/− tumors or indirectly induced by leukocytes 
recruited in the tumor, such as NK cells, DCs and CD8+ T 
lymphocytes, may also account for reduced tumor growth 
and metastasis observed in MMTV-neu/IL-1R8−/− mice. 
Notably, the protected phenotype observed in 
MMTV-neu/IL-1R8−/− mice was not reversed when mice 
were transplanted with IL-1R8+/+ bone-marrow cells, 
supporting an important role played by IL-1R8 expression 
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in non-hematopoietic cells. Since besides leukocytes, cells 
which express highest levels of IL-1R8 are epithelial cells 
[13], we hypothesize that the observed effects on tumor 
growth and progression can be directly attributed to IL-
1R8 expression in tumor cells, which might be sufficient 
to influence the inflammatory and immune responses 
occurring within the TME.
Using immune gene signature analysis, we 
confirmed that high IL-1R8 expression in primary breast 
tumors is significantly associated with impaired innate 
immune sensing and the mobilization of protective 
leukocytes. Using the same approach, we have also 
shown that the majority of primary breast tumors 
displayed a non-T cell inflamed phenotype and that high 
IL-1R8 expression in primary breast tumors is associated 
with lower expression levels of T-cell inflamed signature 
genes. 
Increasing evidence support that current 
immunotherapies such as checkpoint blockade are 
predominantly effective in patients with a pre-existing 
T cell-inflamed tumor microenvironment [52–54]. 
Understanding the molecular mechanisms leading 
to T cell exclusion and to resistance to T cell-based 
immunotherapies would improve patient selection and 
allow the development of novel treatment modalities, 
expanding the fraction of patients benefiting from current 
immunotherapies. In this context, further studies to address 
a putative role for IL-1R8 expression as a prognostic and 
predictive marker for immunotherapy in breast cancer are 
necessary and are worth undertaking. 
Interestingly, pre-clinical studies have demonstrated 
that the use of different agents to induce tissue-based 
inflammation and boost innate immunity, including 
activation of the Stimulator of Interferon Genes (STING) 
and local irradiation, can restore T cell trafficking and 
favorably alter the TME [55, 56]. Based on our findings, 
we propose that IL-1R8 expression in breast tumors 
represents a new immunomodulatory mechanism leading 
to a dysregulated inflammatory response and impaired 
antitumor immunity. Our findings therefore have important 
therapeutic implications and strategies to block IL-1R8 
activity directly or through combined therapies as a way 
to restore innate immune system activation and T cell 
trafficking in breast cancer TME should be further explored. 
MATERIALS AND METHODS
Cell lines and IL-1R8 knockdown
The human mammary epithelial cell line HB4a 
and its variant HB4a – C5.2 were kindly donated by 
Dr. Michael O’Hare (Institute of Cancer Research, 
Sutton, UK). The human natural killer cell line (NKL) 
and the human leukocytic monocyte cell line (THP-1) 
were obtained from American Type Culture Collection 
(Manassas, VA, USA). HB4a-C5.2 cells were transfected 
with two shRNA constructs for IL-1R8 or the empty 
vector (TrifectaTM Kit – IDT, Coralville, IA, USA). 
Co-culture experiments
Cells were treated with 5 ng/mL of IL-1β (R&D 
Systems, Minneapolis, MN, USA). After 24 h, the culture 
supernatant was collected and stored at –80ºC. THP-1 cells 
were cultured for 24 h with supernatants or 25 ng/mL LPS 
(M1-like control) or 30 ng/mL IL-4 (M2-like control). 
Cells were stained with anti-CD206 (eBioscience, San 
Diego, CA, USA), anti-CD86 (BD Biosciences, San Jose, 
CA, USA), anti-CD14 (BD Biosciences) and analyzed 
using FACScantoII (BD Biosciences). For co-culture 
assays with NK cells, human transformed mammary cell 
lines were seeded and allowed to adhere to the plate for 
24 h. NKL cells were added in their complete medium 
and cells were co-cultured for 4h. IFN-γ secretion was 
measured by ELISA.
Animal model
F3 MMTV-neu/IL-1R8+/+ and MMTV-neu/IL-1R8−/− 
female mice were sacrificed at 24 weeks of age or once 
their biggest mammary tumor reached 500 mm3. For 
bone marrow transplantation, 3-weeks old MMTV-neu/
IL-1R8−/− mice were lethally irradiated with a total dose 
of 900 cGy. Mice were then injected in the retro-orbital 
plexus with 5 × 106 nucleated bone marrow cells from IL-
1R8+/+ or IL-1R8−/− donors. All experimental procedures 
were performed according to the Italian animal care and 
ethics legislation and had been approved by the Italian 
Ministry of Health.
FACS analysis
The composition of tumor infiltrate was determined 
by flow cytometry using different combinations of the 
following antibodies: CD45-BV605, CD11b-BV421; Ly6G-
PE-CF594; Ly6C-FITC (Clone AL-21); F4/80-PECy7; 
CD11c-PE; CD3e-FITC; CD4-Alexa700; CD8-PE; CD19-
APC-H7; CD49b(DX5)-APC and MHCII-PercpCy5.5 from 
BD Bioscience, eBioscience or BioLegend (San Diego, CA, 
USA). Cell viability was determined by Aqua LIVE/Dead-
405 nm staining (Invitrogen). Cells were analyzed on LSR 
Fortessa (BD Bioscience).
In silico analysis of gene expression, metagenes 
and immune gene signature analyses
Breast invasive carcinoma Level 3 RNA-Seq 
data were downloaded from TCGA Portal (https://tcga-
data.nci.nih) and molecular subtypes were classified as 
described [57]. Upper quartile normalized RSEM counts 
were used to estimate expression levels of IL-1R8 across 
1,102 tumor samples and 113 normal samples. 792 out of 
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those 1,102 samples, for which molecular classification 
was available, were used to compare IL-1R8 expression 
levels between each subtype. For the metagenes and 
immune gene signature analyses, tumor samples were 
classified into: “IL-1R8-high”, if presenting IL-1R8 
expression greater than the median; and “IL-1R8-low” 
if presenting IL-1R8 expression equal or less than the 
median.
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